February 6th 2024
Drs Mayer and Kalinsky conclude their discussion with a look at agents in development and unmet needs for patients with breast cancer and ESR1 mutations.
January 30th 2024
Medical oncologists discuss oral SERDs, with a focus on the SERENA-2 trial looking at camizestrant in patients with advanced ER+/HER2- breast cancer.
Erica L. Mayer, MD, MPH, discusses the role of elacestrant in the breast cancer treatment landscape and provides clinical insights on its safety profile.
January 23rd 2024
Kevin Kalinsky, MD, MS, gives an overview of recent data from the EMERALD trial investigating elacestrant in patients with ER+/HER2- advanced breast cancer.
Drs Mayer and Kalinsky provide insights and offer their impressions of the PADA-1 trial, focusing on ESR1 mutation monitoring with circulating tumor DNA (ctDNA).
January 16th 2024
Experts on breast cancer discuss challenges encountered in biomarker testing for patients with breast cancer.
Kevin Kalinsky, MD, MS, and Erica L. Mayer, MD, MPH, discuss testing practices for ESR1 mutations in patients with breast cancer.
December 1st 2023
The expert panel concludes the program with key takeaways and closing thoughts on the evolving antibody-drug conjugate space.
November 24th 2023
Experts in breast, lung, and gastric malignancies provide insights on multidisciplinary care in oncology and educating community specialists.
Medical oncologists discuss prospects and challenges in the breast and lung cancer treatment landscapes.
November 17th 2023
Kevin Kalinsky, MD, MS, discusses key takeaways from the 2023 Bridging the Gaps in Breast Cancer meeting, highlighting questions that continue to persist in the treatment of breast cancer.
Specialists in gastric cancer look to the future treatment landscape and review ongoing research in the disease space.
Clinical insights on best practices for treating patients with TROP2-targeted therapy.
November 10th 2023
The expert panel discusses TROP2 as a target for patients with cancer who are receiving antibody-drug conjugates.
A review of antibody-drug conjugates approved for treatment of patients with breast, lung, or gastrointestinal cancers.
November 3rd 2023
Insights on managing antibody-drug conjugate toxicities for patients with gastric cancer.
A GI medical oncologist discusses the role of trastuzumab deruxtecan in the gastric cancer treatment space.
October 27th 2023
A nurse practitioner provides insights on toxicity management strategies for patients with lung cancer who are receiving antibody-drug conjugates.
A medical oncologist reviews the antibody-drug conjugate landscape in lung cancer.
October 20th 2023
Specialists in breast cancer review toxicity management practices for T-DM1 and trastuzumab deruxtecan [T-DXd].